Georgia court approves T(2) settlement:
This article was originally published in Clinica
Executive Summary
The US District Court for the Northern District of Georgia has approved an agreement to settle a consolidated shareholder class action litigation involving T(2) Medical, a subsidiary of Coram Healthcare (Denver). The agreement, announced last October (see Clinica No 623, p 16), resolves litigation relating to claims asserted against T(2) Medical and certain of its former directors and officers, based on events which had occurred prior to the four-company merger which resulted in the formation of Coram. It states that Coram, on behalf of all defendants, will pay to the shareholder class $25 million in cash and will issue warrants to acquire an aggregate of 2.52 million shares of Coram common stock at an initial per-share exercise price of $20.25, subject to adjustment.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.